Instruction 1(b).

FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

**OMB APPROVAL** OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative

defense conditions of Rule 10b5-

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1(c). Si	ee Instruction 1	0.																			
1. Name and Address of Reporting Person* PASSERI DANIEL R						2. Issuer Name <b>and</b> Ticker or Trading Symbol  Cue Biopharma, Inc. [ CUE ]								(Ct	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)						
FASSE											1	Direct	or		10% O	wner					
(Loot)	2 De	O. Data of Fastinat Transaction (Marth/DavNess)									1	Office	r (give title		Other (: below)	specify					
(Last) (First) (Middle) C/O CUE BIOPHARMA, INC.						3. Date of Earliest Transaction (Month/Day/Year) 12/16/2024											EF EXECUTIV		,	ER	
	12,1	12,10,202										,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	LILLOO		2 01110						
40 GUES	_																				
						4. If Amendment, Date of Original Filed (Month/Day/Year)									Individual or Joint/Group Filing (Check Applicable Line)						
(Street)															Form filed by One Reporting Person						
BOSTON MA 02135															Form filed by More than One Reporting						
-													Perso			0	9				
(City)	(Sta	ate) (Z	Zip)																		
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																					
1. Title of	tion					4. Securities Acquired (A)										7. Nature					
Date (Month/Day					y/Year)	//Year) Execution Date, if any (Month/Day/Year)			Code (Instr.		Disposed Of (D) (Instr. 3, 5)		3, 4 an	Benefic Owned Reporte		cially (D) d Following (I) ( ted		) or Indirect (Instr. 4)	of Indirect Beneficial Ownership (Instr. 4)		
											(A) or										
		Code	V	Amount	(A) or (D) Pri				Price		(Instr. 3 and 4)										
Common Stock 12/16/2						.024					30,000	A	\	\$1.03(1)		164,578			D		
		Tal	ole II -	Derivati	ve Se	curit	ties A	Acau	ired. I	Disp	osed of	or Be	enef	ficial	v O	wnec	1		<u> </u>		
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																					
1. Title of Derivative	2. Conversion	3. Transaction Date	3A. Dec	emed ion Date,	4. Transa	action	5. Number on of		6. Date Exercis			7. Title and Amount of Securities Underlying			8. Price of Derivative Security (Instr. 5)		9. Number derivative		f 10. Ownership Form: Direct (D)	11. Nature of Indirect Beneficial Ownership	
Security	or Exercise Price of	(Month/Day/Year)	if any	·	Code (Instr. 8)				(Month					- 1			Securities Beneficially	- [1			
(iiisti. 3)	Instr. 3) Price of (Month/Day/Year) Derivative Security			/Day/Teal)	0,	0)		Acquired					Derivative		(		Owned	´	or Indirect	(Instr. 4)	
							(A) or Disposed of (D) (Instr. 3, 4 and 5)		Security (Ins 3 and 4)				nstr.	tr.		Following Reported		(I) (Instr. 4)			
														Transaction(		n(s)					
																	,,				
														ount							
														mber							
		Code		v	(A)	(D)	Date Exercisable		Expiration Date	Title Sha		ares									
											1										

## **Explanation of Responses:**

1. The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from \$0.97 to \$1.04, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range provided.

> /s/ Daniel Passeri by Colin Sandercock, attorney-in-fact

12/18/2024

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.